Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-03-03

Clinical Trial Update: Open Label Extension of TUDCA-ALS Study [Phase 3]

View source ↗

Summary

Open-label extension update for a Phase 3 TUDCA-ALS trial investigating amyotrophic lateral sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TUDCA (Tauroursodeoxycholic acid)

Snippet

Sponsor: Humanitas Mirasole SpA | Conditions: Amyotrophic Lateral Sclerosis | Phase 3 | Status: UNKNOWN